6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

56 trials found

diseases per page:

Showing 1 to 10 of 56 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04387773 (ClinicalTrials.gov)	November 5, 2020	11/5/2020	Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease	Effect of GOCOVRI on Quantity and Quality of Gait in Parkinson's Disease	Parkinson Disease	Drug: GOCOVRI	Oregon Health and Science University	Adamas Pharmaceuticals, Inc.	Recruiting	50 Years	80 Years	All	12	Phase 4	United States
2	NCT04260581 (ClinicalTrials.gov)	March 1, 2020	5/2/2020	Is Long-term Use of Amantadine Effective in PD?	Is Long-term Use of Amantadine Effective in Parkinson Disease?	Parkinson Disease	Drug: Determination of drug effects through amantadine cessation	Seoul National University Hospital	NULL	Not yet recruiting	40 Years	N/A	All	32	N/A	Korea, Republic of
3	EUCTR2017-002426-20-FR (EUCTR)	05/04/2019	26/11/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinami ...	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, exp ...	Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptiv ...	Zambon SpA	NULL	Not Recruiting			Female: yes Male: yes	177	Phase 4	France;Spain;Austria
4	EUCTR2017-002426-20-IT (EUCTR)	21/02/2019	07/10/2020	Effect of Safinamide on Parkinson's Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinami ...	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON phase, expe ...	Trade Name: Xadago Product Name: Xadago Product Code: [-] INN or Proposed INN: SAFINAMIDE METANSOLFONATO ...	ZAMBON SPA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	177	Phase 4	France;Spain;Austria;Germany;Italy
5	EUCTR2017-002426-20-AT (EUCTR)	22/01/2019	03/12/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinami ...	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, exp ...	Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptiv ...	Zambon SpA	NULL	Not Recruiting			Female: yes Male: yes	105	Phase 4	Spain;Austria
6	EUCTR2017-002426-20-ES (EUCTR)	19/10/2018	20/08/2018	Effect of Safinamide on Parkinson’s Disease Related Chronic Pain	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinami ...	Idiopathic Parkinson's Disease, Hoehn and Yahr stage between 2-3 inclusive during the ON” phase, exp ...	Trade Name: Xadago Product Name: Xadago INN or Proposed INN: Safinamide methansulfonate Other descriptiv ...	Zambon SpA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	177	Phase 4	Spain
7	NCT02589340 (ClinicalTrials.gov)	January 2016	23/10/2015	Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia	Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia	Parkinson's Disease;Dyskinesias;Movement Disorders	Drug: Buspirone;Drug: Placebo	Oregon Health and Science University	Portland VA Medical Center	Terminated	18 Years	99 Years	All	6	Phase 1	United States
8	EUCTR2014-003738-24-AT (EUCTR)	26/06/2015	01/04/2015	A clinical trial to see if ADS-5102 is safe and effective in people with drug induced abnormal movem ...	ADS-5102 (AmantadineHCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients ...	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 17.1;L ...	Product Name: Amantadine HCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amant ...	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	72	Phase 3	Germany;Spain;Austria;United States
9	EUCTR2014-003739-20-AT (EUCTR)	19/06/2015	01/04/2015	A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkin ...	Open-Label Safety Study of ADS-5102 (AmantadineHCl) Extended Release Capsules for the Treatment of L ...	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 18.1;L ...	Product Name: Amantadine HCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amant ...	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	250	Phase 3	United States;Spain;Austria;Germany
10	EUCTR2014-003739-20-DE (EUCTR)	23/04/2015	21/01/2015	A clinical trial to see if ADS-5102 is safe in people with drug induced abnormal movements in Parkin ...	Open-Label Safety Study of ADS-5102 (AmantadineHCl) Extended Release Capsules for the Treatment of L ...	Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease MedDRA version: 18.1;L ...	Product Name: Amantadine HCl Extended Release Capsule Product Code: ADS-5102 INN or Proposed INN: Amant ...	Adamas Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	250	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;United States;Spain;Austria;Germany

First Previous1 2 3 4 5 6Next Last